

Application Number 10/699,362
10/19/2005

6600.200-US
Page 2 of 7

AMENDMENTS TO THE SPECIFICATION

For convenience, directions to amend the application provided herein are made with reference to the paragraph numbers that appear in the published version of the application (i.e., US Patent Publication No. 20050106139).

1. *Please replace paragraph [0204] with the following amended paragraph:*

Fra-1 is cloned by reverse transcription PCR from RNA isolated from 3T3-L1 cells treated for 1 h with dexamethasone, insulin, and BRL49653 using the superscript II kit (Life Technologies) according to the manufacturer's instructions. Id2 and Cyr61 are cloned by reverse transcription PCR from RNA isolated from BHK-TF cells treated for 1 h with FVIIa and from CRL2091 cells treated for 6 hours with FVIIa, respectively. The upstream and downstream primers are: 5'-GCGGCCGCCATGTACCGAGACTACGGGGAACCG-3' (SEQ ID NO:1) and 5'-GCGGCCGCTCACAAAGCCAGGAGTGTAGG-3' (SEQ ID NO:2) for Fra-1, 5'-CAGCATGAAAGCCTTCAGTC-3' (SEQ ID NO:3) and 5'-CTCTGGTGATGCAGGCTGAC-3' (SEQ ID NO:4) for Id2, 5'-CGTCACCCTTCTCCAATTGA-3' (SEQ ID NO:5) and 5'-CTTGGTCTTGCTGCATTTCT-3' (SEQ ID NO:6) for Cyr61. Parameters for PCR are one cycle of denaturing at 94 °C for 10 s, annealing at 65 °C for 15 s, and extension at 72 °C for 1.5 min, one cycle of denaturing at 94 °C for 10 s, annealing at 64 °C for 15 s, and extension at 72 °C for 1.5 min, one cycle of denaturing at 94 °C for 10 s, annealing at 63 °C for 15 s, and extension at 72 °C for 1.5 min, one cycle of denaturing at 94 °C for 10 s, annealing at 62 °C for 15 s, and extension at 72 °C for 1.5 min, one cycle of denaturing at 94 °C for 10 s, annealing at 61 °C for 15 s, and extension at 72 °C for 1.5 min, one cycle of denaturing at 94 °C for 10 s, annealing at 60 °C for 15 s, and extension at 72 °C for 1.5 min, 40 cycles of denaturing at 94 °C for 10 s, annealing at 55 °C for 15 s, and extension at 72 °C for 1.5 min. All fragments are cloned into ~~into~~ TOPO 2.1 (Invitrogen) and sequenced using a Megabase sequencer.

Application Number 10/699,362
10/19/2005

6600.200-US
Page 3 of 7

2. Please replace paragraph [0217] with the following amended paragraph:

[0217] TF antibody variable heavy chains are amplified from cDNA using a degenerated primer mix of: 5'-ACTAGTTTTGGCTGAGGAGACGGTGACCGTGG-3' (SEQ ID NO:7), 5'-ACTAGTTTTGGCTGAGGAGACTGTGAGAGTGG-3' (SEQ ID NO:8), 5'-ACTAGTTTTGGCTGCAGAGACAGTGACCAGAG-3' (SEQ ID NO:9), 5'-ACTAGTTTTGGCTGAGGAGACGGTGACTGAGG-3' (SEQ ID NO:10) and a universal primer mix present in SMART RACE kit supplied by Clontech (kat.# K1811-1).

3. Please replace paragraph [0218] with the following amended paragraph:

TF antibody variable kappa-light chains are amplified from cDNA using 5'-TCATCAACACTCATTCTGTTGAAGCTCTTGA-3' (SEQ ID NO:11) and a universal primer mix present in SMART RACE kit supplied by Clontech (kat.# K1811-1).

4. Please replace paragraph [0220] with the following amended paragraph:

HuTF antibody variable heavy chains are amplified from cDNA of using primer 5'-GTGCCAGGGGGAAGACCGATGGG-3' (SEQ ID NO:12) and a universal primer mix present in SMART RACE kit supplied by Clontech (kat.# K1811-1).

5. Please replace paragraph [0221] with the following amended paragraph:

HuTF antibody variable kappa-light chains are amplified from cDNA using primer 5'-GCAGGCACACAACAGAGGCAGTTCCAGATTTC-3' (SEQ ID NO:13) and a universal primer mix present in SMART RACE kit supplied by Clontech (kat.# K1811-1).